Jump to content

Arbutus Biopharma: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
No edit summary
Line 1: Line 1:
{{Infobox company
| logo =
| logo_caption =
| image =
| image_caption =
| trading_name =
| native_name =
| native_name_lang = fr
| former_name =
| former type =
| type =
| traded_as =
| industry = Pharmaceuticals
| predecessor =
| successor =
| foundation = <!-- City, Country ({{Start date|YYYY|MM|DD}}) -->
| founder =
| location_city =
| location_country = Canada
| locations = <!-- Number of -->
| area_served =
| key_people =
| products =
| brands =
| production =
| services =
| revenue =
| operating_income =
| net_income =
| assets =
| equity =
| owner =
| num_employees =
| parent =
| divisions =
| subsid =
| homepage = <!-- {{URL|example.com}} -->
| footnotes =
| intl =
| bodystyle =
}}
'''Tekmira Pharmaceuticals''' is a Canadian company that is developing an experimental Ebola treatment.
'''Tekmira Pharmaceuticals''' is a Canadian company that is developing an experimental Ebola treatment.



Revision as of 23:41, 21 August 2014

Arbutus Biopharma
IndustryPharmaceuticals
Founded2007 Edit this on Wikidata
Headquarters
Canada

Tekmira Pharmaceuticals is a Canadian company that is developing an experimental Ebola treatment.

TKM-Ebola

The treatment TKM-Ebola was being developed under a $140 million US Department of Defence contract. TKM-Ebola was in phase-1 trials, in July 2014 the US regulatory body placed it on hold due to safety concerns.[1]

2014 outbreak

During the 2014 ebola outbreak their stock price rose significantly.[1]

References

  1. ^ a b Atkins, Richard (9 August 2014). "Biotech Stock in Spotlight: As the World Awaits Ebola Treatment, Tekmira Pharma In Prime Focus". TechNews. Retrieved 10 August 2014.